RESUMO
Cancer is an abnormal and uncontrolled growth of cells that spreads through cell division. There are different types of medicines available to treat cancers, but no drug is found to be fully effective and safe for humans. The major problem involved in the cancer treatments is the toxicity of the established drug and their side effects. Medicinal plants are used as folk medicines in Asian and African populations for thousands of years. 60% of the drugs for treating cancer are derived from plants. More than 3000 plants have anticancer activity. The present review aims at the study of a broad spectrum survey of plants having anticancer components for different type of cancers. This article consists of 364 medicinal plants and their different parts as potential Source of Anticancer Agents.
El cáncer es un crecimiento anormal y descontrolado de células que se disemina a través de la división celular. Hay diferentes tipos de medicamentos disponibles para tratar el cáncer, pero no se ha encontrado ningún medicamento que sea completamente efectivo y seguro para los seres humanos. El principal problema involucrado en los tratamientos del cáncer es la toxicidad del fármaco establecido y sus efectos secundarios. Las plantas medicinales se utilizan como medicinas populares en poblaciones asiáticas y africanas durante miles de años. El 60% de los medicamentos para el tratamiento del cáncer se derivan de plantas. Más de 3000 plantas tienen actividad anticancerígena. La presente revisión tiene como objetivo el estudio de un estudio de amplio espectro de plantas que tienen componentes anticancerígenos para diferentes tipos de cánceres. Este artículo consta de 364 plantas medicinales y sus diferentes partes como fuente potencial de agentes anticancerígenos.
Assuntos
Plantas Medicinais/química , Anticarcinógenos/farmacologia , Compostos Fitoquímicos/análise , Linhagem Celular Tumoral/efeitos dos fármacos , Compostos Fitoquímicos/farmacologiaRESUMO
OBJECTIVE: To determine the knowledge, attitude to and practice of aspirin prescribing by physicians, dispensing by pharmacies and usage by patients in the secondary prevention of myocardial infarction (MI) during the period September 1998 to August 1999. DESIGN AND METHODS: 119 doctors registered with the Trinidad and Tobago Medical Association were administered a questionnaire via a telephone interview on their prescription of aspirin in the secondary prevention of MI. Ninety-four registered pharmacies were administered a similar questionnaire to assess availability of aspirin. Seventy-three patients attending the San Fernando General Hospital (SFGH) and 82 patients from the Eric Williams Medical Sciences Complex (EWMSC) Cardiology clinic with a history of MI were each administered a questionnaire on their use of aspirin. RESULTS: Forty-three doctors (36.1 percent, 95 percent CI: 27.5-45.4) prescribed the recommended dose of 75-100 mg of aspirin for the secondary prevention of MI. Of the 82 patients interviewed from EMSC, 28 (34.2 percent) were taking the recommended dose, as compared with 11 (15.19 percent) patients from SFGH. Throughout Trinidad and Tobago, only 51 pharmacies (54.3 percent, 95 percent CI 43.7-64.6) stocked the required dose. CONCLUSIONS: The prescribing habits, availability and use of the recommended dose of aspirin in the secondary prevention of MI are unacceptable and clearly indicate an urgent need to improve the management of MI.(Au)